


President's Report

C. Randal Mills, Ph.D.
President and Chief Executive Officer
California Institute for Regenerative Medicine

December 11, 2014






Topics

- CIRM Overview
- Program Update
- CIRM 2.0 Update





Our Mission

Accelerating stem cell treatments to patients with unmet medical needs.







668 Awards Since Inception Totaling \$2 Billion



Our Translational and Clinical Programs are Targeting Treatments for 40+ Diseases







- 80 Active Programs
- \$627 Million in Funding



The Majority of our Funding has Gone to Academic Institutions

Industry


Academia



Top 10 Funded Academic Institutions




Institution	Total Awards	ICOC-Approved Funding
Stanford University	97	\$323.7M
University of California, Los Angeles	81	\$240.1M
University of California, San Diego	81	\$165.9M
University of California, San Francisco	68	\$161.8M
University of California, Davis	41	\$139.3M
University of Southern California	28	\$113.4M
University of California, Irvine	38	\$113.3M
Beckman Research Institute of City of Hope	23	\$64.8M
J. David Gladstone Institutes	29	\$64.0M
University of California, Berkeley	22	\$62.4M



Top 10 Funded Industry Partners




Institution	Total Awards	ICOC Approved Funding
ViaCyte, Inc.	6	\$56.0M
StemCells, Inc.	3	\$40.1M
Geron Corporation	2	\$25.0M
Capricor, Inc	1	\$19.8M
Cellular Dynamics International	1	\$16.0M
Asterias Biotherapeutics	1	\$14.3M
Bluebird Bio	1	\$9.4M
Calimmune, Inc.	1	\$8.3M
iPierian, Inc.	2	\$7.1M
Sangamo BioSciences, Inc.	1	\$6.4M



The Number of Clinical Stage Applications and Awards has Fallen




CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE



PROGRAM UPDATE



- Award Description
 - Neural stem cell transplantation for neuroprotection and restoration in Alzheimer's disease
 - \$19.3 million forgivable loan made under the Disease Team II Award program
 - Approved by the ICOC September 2012
- Recipient
 - Stem Cells, Inc.
 - PI: Capela
- Award Status
 - Discontinued due to lack of functional improvement observed in pre-clinical studies
 - \$9,580,807 disbursed



*Building a **better** stem cell agency*
CIRM 2.0





CIRM 2.0: Purpose



*To create a process at CIRM for attracting,
awarding and administering projects that better
serves our mission*





CIRM 2.0 – Starting with Clinical



The Goal is a Better, Faster Product...


But there will be bumps in the road



We must diligently monitor CIRM 2.0



- Objective Metrics of Success
 - Programs advanced
 - Patients treated
 - Product approved
- Surrogate Metrics
 - Number of applications
 - Cycle time
 - Number of awards
 - Quality of awards
- Unintended Effects



CIRM 2.0 Rollout Plan



- January 1st
 - Launch Clinical Stage
 - Market the program
- January 29th Board Meeting
 - Adopt necessary interim policy modifications to the Loan and Grant Administration Policies and GWG bylaws
- Application Review Subcommittee – April 23rd
 - First date possible for awards made under CIRM 2.0
- In 2015
 - Launch Discovery and Translational modules of CIRM 2.0
- Start working on CIRM 3.0



QUESTIONS?





CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Thank you!

C. Randal Mills, Ph.D.

President and Chief Executive Officer
California Institute for Regenerative Medicine